Literature DB >> 10404988

Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease.

C M Clark1, L Sheppard, G G Fillenbaum, D Galasko, J C Morris, E Koss, R Mohs, A Heyman.   

Abstract

OBJECTIVE: To determine the variability in annual Mini-Mental State Examination scores of patients with Alzheimer disease enrolled in the Consortium to Establish a Registry for Alzheimer's Disease (CERAD). PATIENTS: A total of 372 patients with probable Alzheimer disease with 1 or more years of follow-up.
SETTING: Twenty-one CERAD clinical sites throughout the United States.
RESULTS: An average annual decline of 3.4 points in CERAD patients returning for longitudinal reassessments was close to the SD of the measurement error of 2.8 points for the Mini-Mental State Examination. There was wide variability in individual rates of decline. Even with 4 years of follow-up, 15.8% of the patients had no clinically meaningful decline in Mini-Mental State Examination score (defined as a change in initial score >3, ie, 1 SD of measurement error). Validity of measurements of the rate of change in Mini-Mental State Examination scores improved with longer observation intervals and was reliable for most patients when observations were separated by 3 or more years.
CONCLUSIONS: Although the Mini-Mental State Examination is a useful screening instrument to assess level of cognitive function, it has limited value in measuring the progression of Alzheimer disease in individual patients for periods less than 3 years because of a large measurement error and substantial variation in change in annual score.

Entities:  

Mesh:

Year:  1999        PMID: 10404988     DOI: 10.1001/archneur.56.7.857

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  66 in total

1.  Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses.

Authors:  Eric M Blalock; James W Geddes; Kuey Chu Chen; Nada M Porter; William R Markesbery; Philip W Landfield
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

2.  The CERAD Neuropsychologic Battery Total Score and the progression of Alzheimer disease.

Authors:  Heidi C Rossetti; C Munro Cullum; Linda S Hynan; Laura H Lacritz
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Apr-Jun       Impact factor: 2.703

3.  Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease.

Authors:  I Masse; R Bordet; D Deplanque; A Al Khedr; F Richard; C Libersa; F Pasquier
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

4.  Rapid cognitive decline in Alzheimer's disease. Consensus paper.

Authors:  M E Soto; S Andrieu; C Arbus; M Ceccaldi; P Couratier; T Dantoine; J-F Dartigues; S Gillette-Guyonnet; F Nourhashemi; P-J Ousset; M Poncet; F Portet; J Touchon; B Vellas
Journal:  J Nutr Health Aging       Date:  2008-12       Impact factor: 4.075

Review 5.  Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.

Authors:  Robert E Becker; Nigel H Greig
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

Review 6.  Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.

Authors:  David B Hogan
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

7.  Patient and Caregiver Benefit From a Comprehensive Dementia Care Program: 1-Year Results From the UCLA Alzheimer's and Dementia Care Program.

Authors:  David B Reuben; Zaldy S Tan; Tahmineh Romero; Neil S Wenger; Emmett Keeler; Lee A Jennings
Journal:  J Am Geriatr Soc       Date:  2019-07-29       Impact factor: 5.562

8.  Plasma Klotho and Cognitive Decline in Older Adults: Findings From the InCHIANTI Study.

Authors:  Michelle Shardell; Richard D Semba; Caterina Rosano; Rita R Kalyani; Stefania Bandinelli; Chee W Chia; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2015-08-21       Impact factor: 6.053

9.  Cognitive decline and alcohol consumption adjusting for functional status over a 3-year period in French speaking community living older adults.

Authors:  Helen-Maria Vasiliadis; Marie-Christine Payette; Djamal Berbiche; Sébastien Grenier; Carol Hudon
Journal:  J Public Health (Oxf)       Date:  2019-06-01       Impact factor: 2.341

Review 10.  Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes.

Authors:  Amir A Sepehry; Philip E Lee; Ging Yuek R Hsiung; B Lynn Beattie; Claudia Jacova
Journal:  Drugs Aging       Date:  2012-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.